Diagnostic performances of new biomarkers for myocardial infarction exclusion for patients without troponin standard elevation in chest pain unit: a prospective study




Background


Rapid rule out of acute myocardial infarction (AMI) is a major clinical need. Copeptin, as a marker of endogenous stress and highly sensitive troponin assays may be useful in this setting.




Methods


In 80 consecutive patients presenting to the cardiologic emergency department with AMI suggestive symptoms, and a first measurement of standard troponin assay < 0.050 μg/L, we measured copeptin levels (Brahms) at presentation, and those of two different high-sensitivity assays, Roche High-Sensitive Troponin T (TnThs) and Siemens Troponin I ultra (TnIus), at presentation and 6 h later. Finally, we compared the copeptin and high-sensitivity troponin results and their association to the final diagnosis adjudicated by cardiologists.




Methods


In 80 consecutive patients presenting to the cardiologic emergency department with AMI suggestive symptoms, and a first measurement of standard troponin assay < 0.050 μg/L, we measured copeptin levels (Brahms) at presentation, and those of two different high-sensitivity assays, Roche High-Sensitive Troponin T (TnThs) and Siemens Troponin I ultra (TnIus), at presentation and 6 h later. Finally, we compared the copeptin and high-sensitivity troponin results and their association to the final diagnosis adjudicated by cardiologists.

Only gold members can continue reading. Log In or Register to continue

Stay updated, free articles. Join our Telegram channel

Nov 16, 2017 | Posted by in CARDIOLOGY | Comments Off on Diagnostic performances of new biomarkers for myocardial infarction exclusion for patients without troponin standard elevation in chest pain unit: a prospective study

Full access? Get Clinical Tree

Get Clinical Tree app for offline access